Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Icotrokinra was safe and effective for improving skin clearance among patients with at least moderate psoriasis in high-impact areas.

The Johnson & Johnson JNJ stock has risen 4.4% in six months, adding more than $15 billion to its market value. J&J faces ...

Protagonist Therapeutics' partners ought to secure two approvals for blockbuster drugs within the next year. Click here to ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated ...

Icotrokinra (ICO) significantly improves skin clearance and reduces psoriasis severity in high-impact areas, with a safety profile comparable with placebo, according to study results presented at the ...

French biotech Enterome has secured $19 million in private funding to accelerate development of its OncoMimics immunotherapy platform, as it continues to show encouraging early signs of clinical ...

Let's just maybe stay within that and talk a little bit about the oral IL-23, Icotrokinra. Tom Cavanaugh. It's a test. Asad Haider. It's all of the test.

BARCELONA - Johnson & Johnson’s (NYSE:JNJ) Tremfya demonstrated significant ability to inhibit joint structural damage progression in patients with active psoriatic arthritis compared to placebo, ...

Icotrokinra (Johnson & Johnson) Interleukin-23 receptor blocker: Treatment of scalp and genital psoriasis. Phase 3 results: Endocrine Disorders: Somapacitan (Novo Nordisk) Human growth hormone analog: ...